• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Britannia Industries Ltd.
    04 Nov 2022
    6219.50
    0.12%
    Britannia Q2 net up 28.5% to Rs 490 cr, records 'highest quarterly revenue'
    Britannia Q2 net up 28.5% to Rs 490 cr, records 'highest quarterly revenue'
    Business Standard
    Bakery foods company Britannia Industries Ltd on Friday reported a 28.47 per cent increase in consolidated net profit at Rs 490.58 crore for the second quarter ended September 30, 2022, helped by volume growth. The company had posted a net profit of Rs 381.84 crore in the July-September quarter a year ago, Britannia Industries said in a BSE filing. Its total revenue from operations climbed 21.40 per cent to Rs 4,379.61 crore from Rs 3,607.37 crore in Q2 FY22. The company has recorded its "highest quarterly revenue", Britannia Industries said. Total expenses were at Rs 3,773.71 crore in the second quarter of FY23, up 20.25 per cent from Rs 3,138.15 crore in the year-ago period. Britannia Managing Director Varun Berry said, "We have witnessed positive growth momentum over the last few months. Our Go-to-market strategy and increase in distribution reach have converged to deliver a robust topline growth of 22 per cent YoY and 19 per cent QoQ, aided by a mid-single digit volume growth,
    Copy LinkShare onShare on Share on Share on
    Axis Direct upgraded Britannia Industries Ltd. to Buy with a price target of 6750.0 on 05 Sep, 2025.
    Britannia Q2 net profit rises 28% to 490 cr
    livemint | 04 Nov 2022 2 more
    Britannia Q2 results | Net profit rises 28% to Rs 490 crore, revenue jumps 21%
    Moneycontrol | 04 Nov 2022
    Britannia Q2 Preview | Net profit to jump 17% on revenue boost, volume growth pegged at 5%
    Moneycontrol | 04 Nov 2022
    logo
    Nestle India Ltd.
    21 Oct 2022
    1206.60
    -0.49%
    Broker's Call: Nestle (Add)
    Business Line
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 902 to 873 in Jun 2025 qtr
    logo
    Nestle India Ltd.
    20 Oct 2022
    1206.60
    -0.49%
    Nestle stock: Is Maggi-maker's revenue jump high enough to offset margin pressure?
    Nestle stock: Is Maggi-maker's revenue jump high enough to offset margin pressure?
    Economic Times
    "Nestle's strong positioning in the domestic food market, innovative product portfolio and improving out-of-home consumption with a thrust on improving penetration in key markets is helping it to deliver consistent double-digit revenue growth for the past few quarters.
    Copy LinkShare onShare on Share on Share on
    Nestle India Ltd. has an average target of 1340.00 from 11 brokers.
    Nestle India's Q3 volumes shine; levers for margin growth appear limited
    livemint | 20 Oct 2022 2 more
    Nestle India gains 2%, nears 52-week high on strong Q3 revenue growth
    Business Standard | 20 Oct 2022
    Nestle India net profit up 8% to 668 cr
    livemint | 19 Oct 2022
    logo
    Hatsun Agro Products Ltd.
    19 Oct 2022
    909.45
    0.33%
    Hatsun Agro reports a 48% decline in PAT in Q2
    Business Line
    Revenue was up 7 per cent to 1,745 crore
    Copy LinkShare onShare on Share on Share on
    Hatsun Agro Products.. has an average target of 1250.00 from 1 broker.
    logo
    Nestle India Ltd.
    19 Oct 2022
    1206.60
    -0.49%
    Nestle India profit up 8.3% in Sept qtr, net sales growth at five-year high
    Nestle India profit up 8.3% in Sept qtr, net sales growth at five-year high
    Business Standard
    Strong growth in e-commerce channels driven by emerging formats such as 'quick commerce' and 'click & mortar'; E-commerce contribution to sales at 7.2% in the quarter
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 902 to 873 in Jun 2025 qtr
    FMCG major Nestle enters into D2C space, launches online platform
    Business Standard | 19 Oct 2022 9 more
    Nestle India's Q3 net up 8.25%, announces 120/share as interim dividend
    Business Line | 19 Oct 2022
    Accumulate Nestle India; target of Rs 20,111: Prabhudas Lilladher
    Moneycontrol | 19 Oct 2022
    Nestle India's profit up 8.25%, announces interim dividend of 120 per share
    Business Line | 19 Oct 2022
    Nestle Standalone September 2022 Net Sales at Rs 4,591.00 crore, up 18.25% Y-o-Y
    Moneycontrol | 19 Oct 2022
    Nestle India net profit up 8% in September quarter
    livemint | 19 Oct 2022
    Nestle India Q3 results: Profit rises 8% to Rs 668 crore; Rs 120 per share dividend announced
    Business Today | 19 Oct 2022
    Nestle India's profit rises 8.3% to Rs 668 cr in Q2, tops estimates
    Business Standard | 19 Oct 2022
    Nestle India Q3 Results | Revenue grows 18%, profit up 8% with broad based growth across categories
    Moneycontrol | 19 Oct 2022
    Nestle Q3 preview: Gross margin may feel shocks of high inflation in raw materials; likely to announce interim …
    livemint | 18 Oct 2022
    logo
    Heritage Foods Ltd.
    18 Oct 2022
    490.60
    0.28%
    Heritage Foods Standalone September 2022 Net Sales at Rs 808.94 crore, up 22.53% Y-o-Y
    Heritage Foods Standalone September 2022 Net Sales at Rs 808.94 crore, up 22.53% Y-o-Y
    Moneycontrol
    NULL
    Copy LinkShare onShare on Share on Share on
    Heritage Foods Ltd. has an average target of 490.00 from 1 broker.
    logo
    Zydus Wellness Ltd.
    17 Oct 2022
    Split
    2604.90
    2.33%
    Zydus Lifesciences gets USFDA nod for generic Valbenazine, Roflumilast
    Zydus Lifesciences gets USFDA nod for generic Valbenazine, Roflumilast
    Business Standard
    Zydus Lifesciences on Monday said it has got tentative approval from the US health regulator to market its generic versions of Valbenazine capsules and Roflumilast tablets. Valbenazine capsules are indicated for the treatment of tardive dyskinesia (uncontrolled movement of body parts such as face and tongue) while Roflumilast tablets are used for reducing risk of chronic obstructive pulmonary disease in severely affected patients associated with chronic bronchitis and a history of exacerbations. The tentative approval granted by the US Food and Drug Administration (USFDA) to the company's arm Zydus Worldwide DMCC to market Valbenazine capsules is for strengths 40 mg, 60 mg, and 80 mg, Zydus Lifesciences said in a regulatory filing. As per IQVIA MAT August 2022 data, Valbenazine capsules had annual sales of USD 781 million in the US. Zydus further said its US subsidiary Zydus Pharmaceuticals (USA) Inc has also received tentative approval from the USFDA to market Roflumilast tablets
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has gained 63.73% in the last 6 Months
    Zydus Lifesciences gets USFDA nod for 2 generic drugs
    Moneycontrol | 17 Oct 2022
    logo
    Zydus Wellness Ltd.
    13 Oct 2022
    Split
    2604.90
    2.33%
    Hot Stocks | Sun TV Network, Zydus Wellness can give up to 11% return in short term, here's why
    Hot Stocks | Sun TV Network, Zydus Wellness can give up to 11% return in short term, here's why
    Moneycontrol
    Zydus Wellness has recently given a triangle pattern breakout near its long term support area on the weekly timeframe. The 200 EMA is at Rs 1,680 and the stock is comfortably sustaining above it, which can be used as a confluence to the bullish view.
    Copy LinkShare onShare on Share on Share on
    Sharekhan increased Buy price target of Zydus Wellness Ltd. to 2688.0 on 03 Sep, 2025.
    logo
    Zydus Wellness Ltd.
    10 Oct 2022
    Split
    2604.90
    2.33%
    Back-to-back US FDA approvals boost Zydus Lifesciences; stock at 8-month high
    Back-to-back US FDA approvals boost Zydus Lifesciences; stock at 8-month high
    Moneycontrol
    The US accounts for 40 percent of the company's revenue, which is why each FDA approval is a positive
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 126 to 135 in Jun 2025 qtr.
    logo
    Zydus Wellness Ltd.
    07 Oct 2022
    Split
    2604.90
    2.33%
    Mehul Kothari recommends these 2 stocks on 'Symmetrical Triangle' breakout
    Mehul Kothari recommends these 2 stocks on 'Symmetrical Triangle' breakout
    Business Standard
    According to the technical analyst from Anand Rathi, Godfreh Phillips can jump to Rs 1,320, while Zydus Wellness can be bought for a target of Rs 1,860.
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has an average target of 1987.00 from 4 brokers.
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • TechD Cybersecurity
    • L T Elevator
    • Euro Pratik Sales
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd